Opioid Receptor, mu OPRM1, 1 Variant
Pretherapeutic identification of individuals who may require higher or lower doses of opioid drugs to achieve adequate pain control or have a better response to naltrexone for the treatment of alcohol and/or opioid dependency.
Polymerase Chain Reaction (PCR)/Fluorescence Monitoring
New York DOH Approval Status
Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Plasma or serum. Heparinized specimens. Frozen specimens in glass collection tubes.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month
Refer to report
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2008769||OPRM1 Genotype, Interpretation||94415-7|
|3005505||OPRM1 Phenotype, Interpretation||81259-4|
- Opioid receptor sensitivity (Opioid Receptor, Mu (OPRM1) Genotype, 1 Variant)